Atabecestat
- Generic Name
- Atabecestat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H14FN5OS
- CAS Number
- 1200493-78-2
- Unique Ingredient Identifier
- 2834W8D6GK
- Background
Atabecestat is under investigation in clinical trial NCT02211079 (A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates).
- Associated Conditions
- -
- Associated Therapies
- -
Characterization of T-Cell Response in Participants Previously Treated With JNJ-54861911 (Atabecestat)
- First Posted Date
- 2018-07-16
- Last Posted Date
- 2019-10-07
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 9
- Registration Number
- NCT03587376
- Locations
- 🇧🇪
Ziekenhuis Hoge Beuken, Hoboken, Belgium
🇫🇷Hôpital Fernand Widal, Paris, France
🇪🇸Fundacion Ace, Barcelona, Spain
A Pharmacokinetic Interaction Study Between JNJ-54861911 and Transporter Substrates Rosuvastatin and Metformin in Healthy Participants
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT02611518
A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-08-07
- Last Posted Date
- 2015-11-24
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT02211079
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath